ratutrelvir (TRX01) / Traws Pharma - LARVOL DELTA

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Traws Pharma, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Traws Pharma, Inc.

New P2 trial • Infectious Disease • Novel Coronavirus Disease

A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered 83-0060 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers (ANZCTR) - P1 | N=64 | Completed | Sponsor: Trawsfynydd Therapeutics AU Pty Ltd (on behalf of Traws Pharma, Inc) | Recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Traws Pharma, Inc. | Trial completion date: Sep 2024 ➔ Dec 2024

Trial completion date

A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered 83-0060 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers (ANZCTR) - P1 | N=64 | Recruiting | Sponsor: Trawsfynydd Therapeutics AU Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Apr 2024

Enrollment open • Trial initiation date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Traws Pharma, Inc.

New P1 trial